CM
NTLA icon

Caption Management’s Intellia Therapeutics NTLA Stock Holding History

Caption Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$255K – 1901
2025
Q4 		$180K Buy
20,000
+19,872
+15,525% +$274K ﹤0.01% 1391
2025
Q3 		$2.21K Sell
128
-12,548
-99% -$155K ﹤0.01% 1602
2025
Q2 		$119K Hold
12,676
– – ﹤0.01% 1308
2025
Q1 		$90.1K Sell
12,676
-42,324
-77% -$428K ﹤0.01% 1366
2024
Q4 		$641K Buy
55,000
+54,100
+6,011% +$844K 0.01% 1026
2024
Q3 		$18.5K Sell
900
-5,100
-85% -$118K ﹤0.01% 1207
2024
Q2 		$134K Sell
6,000
-9,616
-62% -$229K ﹤0.01% 997
2024
Q1 		$430K Buy
+15,616
New +$434K 0.01% 904
2023
Q4 		– Sell
-500
Closed -$14.4K – 1553
2023
Q3 		$15.8K Buy
+500
New +$19.4K ﹤0.01% 1219
2023
Q1 		– Sell
-1,550
Closed -$60.8K – 1396
2022
Q4 		$54.1K Sell
1,550
-12,056
-89% -$573K ﹤0.01% 1172
2022
Q3 		$762K Sell
13,606
-22,574
-62% -$1.4M 0.01% 959
2022
Q2 		$1.87M Buy
36,180
+31,880
+741% +$1.62M 0.03% 689
2022
Q1 		$312K Buy
4,300
+2,314
+117% +$196K ﹤0.01% 1206
2021
Q4 		$234K Buy
+1,986
New +$249K ﹤0.01% 1395
2021
Q2 		– Sell
-37,701
Closed -$2.94M – 1490
2021
Q1 		$3.03M Buy
+37,701
New +$2.53M 0.07% 393

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caption Management's NTLA Position: Q1 2026 in Review

Caption Management sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 20,000 shares — an estimated $255K sold.

Caption Management first reported a position in NTLA in Q1 2021 and held it in 15 quarters. The position peaked at $3.03M in Q1 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Caption Management reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 20,000 Intellia Therapeutics shares in Q1 2026, an estimated $255K.
  • Caption Management first reported a position in Intellia Therapeutics in Q1 2021 and held it in 15 quarters.
  • Caption Management's Intellia Therapeutics position peaked at $3.03M in Q1 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.